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Abstract
Objective:  To  present  the  main  results  of  the  literature  on  genetic  polymorphisms  in  Turner
syndrome  and  their  association  with  the  clinical  signs  and  the  etiology  of  this  chromosomal
disorder.
Data sources: The  review  was  conducted  in  the  PubMed  database  without  any  time  limit,  using
the terms  Turner  syndrome  and  genetic  polymorphism.  A  total  of  116  articles  were  found,  and
based on  the  established  inclusion  and  exclusion  criteria  17  were  selected  for  the  review.
Data synthesis:  The  polymorphisms  investigated  in  patients  with  Turner  syndrome  were  asso-
ciated with  growth  deﬁcit,  causing  short  stature,  low  bone  mineral  density,  autoimmunity  and
cardiac abnormalities,  which  are  frequently  found  in  patients  with  Turner  syndrome.  The  role
of single  nucleotide  polymorphisms  in  the  etiology  of  Turner  syndrome,  i.e.,  in  chromosomal
nondisjunction,  was  also  conﬁrmed.
Conclusions:  Genetic  polymorphisms  appear  to  be  associated  with  Turner  syndrome.  However,
in view  of  the  small  number  of  published  studies  and  their  contradictory  ﬁndings,  further  studies
in different  populations  are  needed  in  order  to  clarify  the  role  of  genetic  variants  in  the  clinical
signs and  etiology  of  the  Turner  syndrome.
© 2015  Sociedade  de  Pediatria  de  São  Paulo.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.PALAVRAS-CHAVE
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Síndrome  de  Turner  e  polimorﬁsmo  genético:  uma  revisão  sistemática
Resumo
Objetivo:  Apresentar  os  principais  resultados  dos  estudos  que  investigaram  polimorﬁsmos
genéticos em  síndrome  de  Turner,  bem  como  sua  associac¸ão  com  alguns  sinais  clínicos  e  etiologia
desse distúrbio  cromossômico.
DOI of original article: http://dx.doi.org/10.1016/j.rpped.2014.11.014
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Fontes  de  dados:  Revisão  bibliográﬁca  feita  no  PubMed,  sem  limite  de  período,  com  os
seguintes termos:  Turner  syndrome  and  genetic  polymorphism.  Foram  identiﬁcados  116  artigos
e, de  acordo  com  os  critérios  de  inclusão  e  exclusão,  17  foram  selecionados  para  leitura.
Síntese  dos  dados:  Os  polimorﬁsmos  investigados  em  pacientes  com  síndrome  de  Turner
estavam  relacionados  com  déﬁcit  de  crescimento,  que  causou  baixa  estatura,  densidade  mineral
óssea baixa,  autoimunidade  e  anomalias  cardíacas,  que  podem  estar  presentes  com  frequên-
cias signiﬁcativas  nas  pacientes.  Também  foi  veriﬁcado  o  papel  dos  polimorﬁsmos  de  único
nucleotídeo  (SNPs)  na  etiologia  da  síndrome  de  Turner,  ou  seja,  na  não  disjunc¸ão  cromossômica.
Conclusões:  Os  polimorﬁsmos  genéticos  parecem  estar  associados  à  síndrome  de  Turner.  Entre-
tanto, por  conta  dos  poucos  estudos  publicados  e  dos  achados  contraditórios,  pesquisas  em
diferentes  populac¸ões  são  necessárias  para  esclarecer  o  papel  dessas  variantes  genéticas  para
os sinais  clínicos  e  a  etiologia  do  distúrbio  cromossômico.
© 2015  Sociedade  de  Pediatria  de  São  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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he  description  of  female  patients  with  Turner  syndrome
TS)  was  published  in  1938  by  Henry  Turner1;  however,
n  1930,  German  pediatrician  Dr.  Otto  Ullrich  had  already
eported  a  case  of  an  8-year-old  girl  with  signs  suggestive  of
S.2 Therefore,  this  syndrome  is  also  called  Ullrich-Turner
yndrome.
The  disorder  has  an  incidence  of  1/2500  girls  and
linical  signs  include  lymphedema  of  hands  and  feet,
hort  and  webbed  neck,  low  hairline  at  the  nape  of  the
eck,  cubitus  valgus,  hypoplastic  or  hyperconvex  nails,
icrognathia,  high-arched  palate,  short  stature,  gonadal
ysgenesis,  primary  amenorrhea,  sexual  infantilism,  infertil-
ty,  shield  chest,  breast  hypertelorism,  cardiac  (coarctation
f  the  aorta  and  ventricular  septal  defects)  and  renal
nomalies  (horseshoe  kidney,  urethral  duplication  and  uni-
ateral  kidney  agenesis),  multiple  pigmented  nevi,  scoliosis,
ourth/ﬁfth  metacarpal  or  metatarsal  hypoplasia  or  both.
he  following  problems  may  also  be  present:  hearing  impair-
ent,  arterial  hypertension,  osteoporosis,  obesity,  visual
isturbances,  impaired  glucose  tolerance,  learning  disabil-
ties,  psychosocial  problems  and  thyroid  diseases,  among
ther  autoimmune  diseases.3
TS  is  characterized  by  large  phenotypic  variability,  rang-
ng  from  the  classical  form  (girls  with  pubertal  development
nd  growth  delay)  to  those  with  few  dysmorphic  signs,  which
re  almost  indistinguishable  from  the  general  population.4
he  deﬁnitive  diagnosis  of  TS  is  carried  out  by  analyzing  the
aryotype,  which  allows  the  identiﬁcation  of  the  individ-
al’s  chromosomal  constitution.  TS  chromosomal  etiology
as  only  elucidated  in  1959,  when  the  ﬁrst  patient  was
nvestigated  by  cytogenetics  and  showed  the  45,  X  chro-
osomal  constitution.5 Brazilian  studies  in  patients  with  TS
howed  that  the  karyotype  45,  X,  i.e.,  monosomy  of  the  sex
hromosome  X,  was  found  in  40--60%  of  patients  with  TS,
ut  mosaicisms  and  karyotypes  with  structural  alterations,
4,6--8ainly  isochromosomes,  are  also  found. A  retrospective
tudy  indicated  that  better-quality  diagnosis  has  improved
he  quality  of  the  cytogenetic  result  of  TS,  with  modiﬁcation
f  the  proportion  between  the  types  of  karyotype  observed,
a
o
nspecially  the  progressive  decrease  in  the  identiﬁcation  of
5,  X  patients  and  increased  detection  of  karyotypes  with
tructural  aberrations.6
In  Brazil,  the  mean  age  of  TS  diagnosis  is  around  12  years
f  age,4,7,9,10 and  25.3%  and  51.1%  of  the  patients  were
espectively  diagnosed  in  childhood  (1--11  years)  and  ado-
escence  (12--18  years),  on  account  of  the  short  stature.7
herefore,  it  is  important  to  assess  girls  with  short  stature,
egardless  of  the  presence  of  typical  dysmorphic  signs  and
ubertal  delay,  by  requesting  the  karyotype  analysis  to
onﬁrm  or  rule  out  TS.  The  authors  also  point  out  that
eonatologists  and  pediatricians  should  be  aware  about  the
ossibility  of  genetic  syndromes  such  as  TS,  considering  that
he  main  signs  are  present  at  birth,  but  are  not  taken  into
ccount  at  that  time.7 Thus,  medical  training  improvement
imed  to  recognize  the  spectrum  of  clinical  manifestations
f  this  chromosomal  syndrome  is  necessary.  In  addition  to
he  difﬁculty  of  achieving  an  early  diagnosis  of  this  genetic
ondition,  other  factors  associated  with  late  TS  diagnosis
nclude  less  severe  growth  retardation,  presence  of  spon-
aneous  pubertal  signs,  socioeconomic  determinants  and
bsence  of  obvious  dysmorphic  features.4,10
Early  diagnosis  of  TS  is  vital,  as  it  also  allows  the  iden-
iﬁcation  of  congenital  and  acquired  anomalies,  as  well
s  the  detection  of  cases  with  Y  chromosome  sequences
n  the  karyotype,  which  is  associated  with  gonadoblas-
oma,  a tumor  with  high  malignant  potential  that  can
e  prevented  through  prophylactic  gonadectomy,11 besides
llowing  hormonal  treatments  with  growth  hormone  (GH)
nd  oxandrolone12 and  estrogen/progestogen12,13 to  respec-
ively  increase  ﬁnal  height  and  accentuate  secondary  sexual
haracteristics  at  the  adequate  chronological  age,  pre-
enting  further  damage  to  patient  health.  Therefore,  an
arly  and  accurate  diagnosis  is  important  for  a  success-
ul  therapeutic  approach.  It  is  noteworthy  that  there  is
o  classical  karyotype  or  phenotype  associated  with  TS,
nd  the  diagnosis  is  not  always  evident,  but  should  be
ctively  sought,  both  from  a  clinical  and  cytogenetic  point
f  view.6
Additionally,  TS  is  a genetic  disorder,  and  single
ucleotide  polymorphisms  (SNPs)  may  be  involved  in  its
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etiology.  SNPs,  which  are  deﬁned  as  a  change  that  can  occur
in  one  of  every  1000  base  pairs,  are  common  in  the  human
genome  and  are  involved  in  several  human  diseases.  They
correspond  to  genetic  alterations  present  in  more  than  1%
of  the  population  and  can  be  located  in  different  regions
of  the  gene:  promoter,  coding  and  non-coding.  SNPs  in  the
coding  and  promoter  regions  are  more  likely  to  alter  gene
function  and,  consequently,  the  formed  protein.14
In  this  context,  this  study  aims  to  review  the  main  results
of  the  studies  investigating  genetic  polymorphisms  in  TS,  as
well  as  their  association  with  clinical  signs  and  etiology  of
this  chromosomal  disorder.
Method
The  present  study  is  a  literature  review,  with  a  descriptive
approach.  A  survey  was  carried  out  in  PubMed,  in  July  2014,
without  time  limit,  using  the  following  terms:  Turner  syn-
drome  and  genetic  polymorphism.  The  PubMed  database  was
chosen  for  this  systematic  review  because  it  is  more  compre-
hensive  and  internationally  used  for  researches  in  the  health
area.
Inclusion  criteria  were  articles  closely  related  to  the
topic  and  selection  was  based  on  titles  and/or  abstracts,
full  article  availability  and  publication  in  English  and/or  Por-
tuguese.  The  ones  that  did  not  meet  the  abovementioned
criteria  were  excluded.
A  total  of  116  articles  were  found.  Of  these,  14  were
selected  and  102  excluded.  Of  the  excluded  ones,  21  con-
tained  the  term  Turner  in  the  list  of  authors.  The  reference
lists  of  the  included  articles  were  also  assessed  to  iden-
tify  relevant  studies  not  detected  by  the  electronic  search.
Based  on  the  established  inclusion  criteria,  we  selected
three  more  studies,  totaling  17.
Results
The  main  results  of  the  17  studies15--31 included  in  this  sys-
tematic  review  are  shown  in  Table  1.
Discussion
The  present  study  is  a  review  article  on  studies  about  contri-
bution  of  polymorphisms  to  the  manifestations  of  TS,  its
etiology  and  response  to  treatment.  SNPs  shown  in  Table  1
are  related  to  growth  deﬁcit,  leading  to  short  stature,
low  bone  mineral  density,  autoimmunity  and  heart  abnor-
malities;  these  characteristics  are  present  at  signiﬁcant
frequency  in  patients  with  TS.  The  role  of  polymorphisms
in  the  etiology  of  TS,  namely,  the  chromosomal  non-
disjunction,  was  also  demonstrated.
Short  stature
One  of  the  main  clinical  signs  of  TS  is  short  stature,
which  was  present  in  97%  and  100%  of  patients  with  TS
assessed.7,8 Thus,  growth  hormone  therapy  (GHT)  is  given
to  these  patients  to  increase  their  ﬁnal  adult  height.  GH
exerts  its  biological  functions  by  direct  binding  to  the
GHR  (Growth  Hormone  Receptor)  or  indirectly  via  IGF-1
t
r
m
p365
Insulin-Like  Growth  Factor)  in  synergy.32 Therefore,  poly-
orphism  in  the  GHR  may  affect  the  response  to  GH  therapy
n  patients  with  TS.
The  GHR  gene  is  located  on  5p13.1-p12  and  has  two  dif-
erent  isoforms:  a  complete  or  full-length  (GHRﬂ)  and  one
ith  deletion  of  exon  3  (GHRd3).  Three  possible  genotypes
an  be  observed:  ﬂ/ﬂ,  ﬂ/d3  and  d3/d3,  with  the  latter  being
he  one  with  the  lowest  frequency.  The  GHRd3  polymor-
hism  was  evaluated  in  seven  studies  regarding  its  inﬂuence
n  response  to  therapy  with  recombinant  human  growth
ormone  (rhGH)  in  patients  with  TS.  Four  studies  have  inves-
igated  this  SNP  alone15,17,19 and  three,  its  role  alone  and
n  combination  with  polymorphisms  in  the  VDR  (vitamin  D
eceptor),  IGFBP3  (insulin-like  growth  factor  binding  pro-
ein)  and  SOCS2  (suppressor  of  cytokine  signaling)  genes,
ia  gene-gene  interaction.18,20,21 The  results  obtained  by
he  German15,16 and  Brazilian  groups20,21 reported  a  posi-
ive  association  between  the  investigated  SNPs  and  growth
esponse  to  rhGH  therapy.  The  VDR  gene  is  important  for
eight  because  it  interferes  with  calcium  and  phosphate
omeostasis,  inﬂuencing  skeletal  growth.18 Additionally,
olymorphisms  inherited  from  the  VDR  gene  can  affect  IGF
ignaling  and  in  turn,  response  to  rhGH  in  patients  with  GH
eﬁciency  and  TS.  The  polymorphisms  −202  A/C  IGFBP3
nd  SOCS-2  are  involved  in  the  pharmacogenetics  of  rhGH
nd  negative  regulation  of  GHR  signaling,  respectively.20,21
n  one  of  these  studies,  the  authors  suggest  the  use  of
hese  genetic  markers  to  identify,  among  patients  treated
ith  rhGH,  those  genetically  predisposed  to  have  less  favor-
ble  results.21 The  homozygous  state  for  the  d3-GHR  allele
as  associated  with  weight  control  and  body  mass  index
BMI)  in  TS  in  one  study,16 but  not  in  another.17 Regard-
ng  growth,  polymorphisms  in  the  GHR  gene  contributed  to
herapy  response  alone15 or  in  combination.20,21 One  of  the
tudies20 mentioned  that  the  possible  reasons  for  the  lack  of
orrelation  in  two  previous  studies  included  the  small  num-
er  of  patients  evaluated18 and  the  fact  that  few  individuals
re  carriers  of  the  d3  allele.17 The  latter  study  reported
hat  the  genotypes  of  the  GHR  gene  could  not  be  divided
n  three  groups  as  a  consequence  of  the  low  frequency  of
llele  d3,  which  could  have  led  to  negative  results.17 The
hree  studies  that  showed  negative  association  of  the  d3-
HR  polymorphism  were  carried  out  in  Korea,  Venezuela
nd  Turkey.17--19 One  of  them18 reported  that  the  study  was
imited  by  sample  size.  However,  the  ﬁndings  were  the  prod-
ct  of  a  prospective  study18 and  the  previous  researches
ere  retrospective.15--17 The  need  for  prospective  studies
as  reported  by  two  studies.17,20 One  way  to  increase  sample
ize  is  to  perform  multicenter  studies,  such  as  those  car-
ied  out  by  Ko  et  al.17 and  Bas¸  et  al.,19 both  retrospective.
n  the  ﬁrst  study,  the  175  patients  with  TS  were  from  20
ospitals  in  Korea.17 The  study  published  in  2012  reportedly
ncluded  the  largest  number  of  patients  among  studies  car-
ied  out  so  far,  but  only  evaluated  43  patients  with  TS,19
 number  similar  to  that  of  non-multicenter  studies.15,16
ecause  of  the  difﬁculty  in  obtaining  large  and  homogeneous
amples  of  patients  with  TS  and  GH  deﬁciency,  multicen-
er  studies  and/or  meta-analyses  are  needed  to  conﬁrm
he  role  of  this  polymorphism  in  the  pharmacogenetics  of
hGH.21 It  is  also  noteworthy  that,  in  relation  to  GH  treat-
ent  in  children  with  TS,  two  recent  studies  employing
harmacogenomic  methods  were  published  by  the  same
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Table  1  Summary  of  key  ﬁndings  of  17  studies  that  evaluated  genetic  polymorphisms  in  Turner  syndrome.
Gene/Reference  Sample  size  Origin  Main  ﬁndings  or  conclusion
GHR
Binder  et  al.15
53  girls  with  short  stature
due  to  TS
Germany Girls  with  TS  treated  with  rhGH  therapy
and  carriers  of  one  or  two  d3  alleles
showed  increased  growth  rate,
exceeded  the  projected  growth  and
showed  a  gain  of  1.5cm  in  height
60 children  small  for  GA
62  controls
GHR
Binder  et  al.16
48  women  with  TS  Germany  d3-GHR  in  homozygous  state  was
associated  with  gain  in  height  and  the
mean  weight  and  BMI  were  lower  in
Group  d3/d3  in  patients  undergoing  GH
therapy
GHR
Ko et  al.17
175  patients  with  TS Korea The  d3-GHR  genotype  was  not
associated  with  growth  and  weight  (BMI)
in TS  patients  undergoing  GH  therapy
100 controls
GHR  and  VDR
Alvarez-Nava  et  al.18
28  children  with  GHD Venezuela Polymorphisms,  either  individually  or  in
combination,  did  not  contribute  to  GH
therapy  response
25 patients  com  TS
100  healthy  adults
GHR
Bas¸  et  al.19
218  patients  with  GHD Turkey Response  to  GH  therapy  does  not  depend
on  d3-GHR  genotypes43 patients  with  TS
477  adult  controls
GHR and  IGFBP3
Braz  et  al.20
112  patients  with  TS Brazil  Patients  carrying  at  least  one  GHR-d3
allele  or  −202  A  IGFBP3  had  higher
growth  rate  and  became  taller  adults
than  those  homozygous  for  GHR-ﬂ  or
−202C  IGFBP3,  with  the  two  latter  ones
being  associated  with  less  favorable
growth  results  after  rhGH  treatment
GHR, IGFBP3  and  SOCS2
Braz  et  al.21
65  patients  with  TS
47  height  patients  with  GHD
Brazil  Polymorphism  SOCS2  alone
(allele  C)  showed  inﬂuence
on adult  height.  SOCS2  --  T,
GHR-ﬂ  and  −202C  IGFBP3  in
homozygous  state  were
unfavorable  genotypes  for
adult  height
VDR
Peralta-López  et  al.22
65  women  with  TS
110  genotype  healthy
Argentina Polymorphisms  BsmI  and  FokI,  genotypes
bb  and  ff  respectively,  were  associated
with  lower  BMD,  whereas  the
polymorphic  site  ApaI  was  not.
Osteocalcin  and  -CrossLaps,  markers  of
bone  formation  and  resorption,
respectively,  were  similar  in  patients
with  TS,  regardless  of  the  genotype
VDR
Peralta-López  et  al.23
55  patients  with  TS
59  control  women
Argentina Patients  with  the  GG  genotype  of
polymorphism  Cdx2  showed  higher  levels
of osteocalcin  and  -CrossLaps,  i.e.,
markers  of  bone  formation  and
resorption,  respectively
ER-
Sowinska-Przepiera
et al.24
32  patients  with  TS
82  therapy  healthy  control
women
Poland  The  recessive  homozygous  genotypes  (xx
and pp)  of  polymorphism  XbaI  and  PvuII
were  considered  good  markers  of  bone
mineralization  in  patients  undergoing
estroprogestagen  therapy
VDR
Bianco et  al.25
101  women  with  TS
133  healthy  fertile  women
without  history  of
autoimmune  disease
Brazil  Individual  analysis  of  the  four
polymorphisms  (ApaI,  TaqI,  FokI  and
BsmI)  and  by  haplotype  showed  no
association  with  thyroid  abnormalities
and  TS
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Table  1  (Continued)
Gene/Reference  Sample  size  Origin  Main  ﬁndings  or  conclusion
PTPN22
Bianco  et  al.26
142  women  with  TS
180  healthy  and  fertile
women  without  history  of
autoimmune  disease
Brazil  Genotype  frequencies  of  polymorphism
C1858T  were  statistically  different  in
TS,  suggesting  that  this  SNP  could  be  a
major  genetic  risk  factor  that
predisposes  to  autoimmune  disease  in
Brazilian  patients  with  TS
AT2R
Struwe et  al.27
97  patients  with  Coa Germany  A→G  transition  at  position  1675  in
intron  1  of  AT2R  gene  is  not  associated
with  the  pathogenesis  of  CoA  and/or  TS
28 patients  with  TS
10  patients  with  CoA  and  TS
96 healthy  children
MTHFR
Santos  et  al.28
49  patients  with  TS
200  apparently  healthy
individuals
Brazil  Individuals  with  TS  showed  an  increase
in the  frequency  of  homozygous
genotype  C677T,  indicating  possible  risk
factor  for  chromosomal  non-disjunction
as it  decreases  the  activity  of  the  MTHFR
enzyme
MTHFR
Oliveira et  al.29
140  patients  with  TS Brazil  In  patients  with  TS,  the  1298CC  genotype
was more  frequent  and  associated  with
increased  risk  of  aneuploidy
209 healthy  fertile  women
with  no  children  with
chromosomal  aneuploidy
MTHFR
Oliveira  et  al.30
78  women  with  TS Brazil  Polymorphism  MTHFR  A1298C  (allele  C)
and the  two  haplotypes  CC  and  TC  of
SNPs  MTHFR,  C677T  and  A1298C  were
also  associated  with  TS
372 healthy  individuals
without  personal  or  family
history  of  cardiovascular
disease  and  cancer
EFHC2
Zinn et  al.31
97  Caucasian  patients  with
TS
USA  Polymorphism  rs7055196  was  not
associated  with  fear
TS, Turner syndrome; rhGH, recombinant human growth hormone; GH, growth hormone; BMI, body mass index; GHD, GH deﬁciency;
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group  of  researchers  seeking  to  establish  an  individualized
therapy.33,34
Positive  associations  have  been  reported  only  for  indi-
viduals  of  the  same  ethnic  origin.15,16,20,21 In  spite  of  the
contradictory  results  regarding  GHRd3  polymorphism,  a
recent  review  showed  the  implications  of  this  SNP  in  clinical
practice  and  concluded  it  constitutes  a  predictive  factor  of
better  response  to  hormone  replacement  therapy  in  patients
with  short  stature.32 Two  other  meta-analysis  studies35,36
carried  out  by  independent  groups,  also  conﬁrmed  the  inﬂu-
ence  of  this  polymorphism  in  response  to  growth  in  children
with  short  stature  treated  with  rhGH.  However,  these  two
meta-analyses  included  a  maximum  of  three  studies  of  rhGH
therapy  effect  and  its  relation  to  genotype  d3-GHR  in  TS,
which  highlights  the  need  for  additional  investigations.35,36
Bone  mineral  density
TS  patients  have  low  bone  mineral  density  (BMD),  but  it
can  be  maintained  at  normal  levels  if  the  patient  follows
a  healthy  lifestyle  with  regular  practice  of  physical  exer-
cise,  early  introduction  of  an  appropriate  dose  of  estrogens
(hormone  replacement  therapy),  as  well  as  calcium  and
vitamin  D.3,37 The  VDR  gene  binds  to  the  active  form  of
vitamin  D  to  modulate  gene  transcription.  Vitamin  D,  in
turn,  is  a  steroid  hormone  which  regulates  bone  metabolism,
T
t
d nucleotide polymorphisms; GA, gestational age.
mmune  response,  cell  proliferation  and  differentiation.38
itamin  D  deﬁciency  is  associated  with  increased  risk  of
ractures,  autoimmune  diseases,  type  1  and  2  diabetes,
ypertension  and  heart  disease,38 clinical  characteristics
resent  in  patients  with  TS.3 Considering  the  abovemen-
ioned  facts,  the  VDR  gene  was  investigated  in  four  studies,
ne  of  them  associated  with  growth,18 two  with  BMD22,23
nd  one  with  thyroid  anomalies.25 The  BsmI,  FokI  and  Cdx2
olymorphisms  were  positively  associated  with  bone  den-
ity,  and  early  detection  of  these  polymorphisms  could  be
seful  for  predicting  severe  osteopenia  in  patients  with
S.22,23 Another  study  showed  a  positive  association  between
olymorphisms  in  the  ER- gene  (estrogen  receptor-alpha)
nd  BMD  in  patients  with  TS  undergoing  treatment  with
stroprogestagen.24 Patients  with  TS  have  estrogen  deﬁ-
iency  as  a  result  of  ovarian  failure,  and  hypoestrogenism
lays  a  vital  role  in  bone  mineralization  disorders.  Thus,  hor-
one  replacement  therapy  with  estrogen  contributes  to  the
evelopment  of  secondary  sexual  characteristics  and  opti-
izes  peak  bone  mass,  preventing  osteoporosis.39
utoimmunityS  patients  have  high  risk  for  autoimmune  diseases,  with
he  most  common  being  those  related  to  the  thyroid.  A
escriptive  study  showed  that  cardiovascular  anomalies
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45%),  otitis  (43%),  thyroid  dysfunction  (33%)  and  hyper-
ension  (26.6%)  were  the  most  frequent  clinical  alterations
bserved  in  42  patients  with  TS.8 Polymorphisms  in  the
DR  and  PTPN22  gene  (Protein  Tyrosine  Phosphatase,
on-receptor  type  22)  were  investigated  by  the  same  group
f  researchers  to  verify  their  association  with  autoimmune
hyroid  diseases  in  patients  with  TS.25,26
The  allelic  variation  of  the  PTPN22  gene,  C1858T,  was
ssociated  with  the  risk  of  autoimmune  diseases  in  Brazilian
atients  with  TS.26 The  study  published  in  2012  reported
hat  one  of  its  main  limitations  was  the  small  number
f  patients  with  TS  and  thyroid  disorders  --  only  22  --
hich  reduced  the  statistical  power  to  detect  associations
etween  polymorphisms  of  the  VDR  gene  and  autoim-
une  diseases  in  TS.25 However,  both  researches  suggest
hat  further  studies  involving  a  larger  number  of  patients
e  carried  out  to  assess  whether  this  association  exists
r  not.
ardiovascular  malformation
ardiovascular  malformations  are  the  highest  contributors
o  morbidity  and  mortality  in  girls  with  TS,  especially  as
 result  of  aortic  dissection  risk  and,  therefore,  they  can
hange  life  expectancy  of  these  patients.40 The  most  com-
on  are  coarctation  of  the  aorta  (CoA),  bicuspid  aortic
alve  and  hypoplastic  left  heart.3 CoA  and  bicuspid  aor-
ic  valve  were  present  in  6.9%  and  21%,  respectively,  of
33  French  patients  with  TS  assessed  for  cardiovascular
ndings,41 with  a  19%  frequency  being  found  in  another
tudy.9 One  gene  associated  to  cardiovascular  diseases  is
T2R  (Angiotensin  Type  2  Receptor);  however,  polymorphism
→G  does  not  seem  to  be  involved  in  the  pathogenesis  of
oA  in  individuals  with  and  without  TS.27 A  recent  study
howed  that  5.3%  of  girls  with  CoA  were  diagnosed  with
S  when  karyotyping  was  carried  out.  The  authors  conclude
hat  all  girls  with  CoA  should  undergo  karyotyping,  with  a
inimum  count  of  50  cells  at  the  time  of  heart  disease
iagnosis.42
Previous  studies  have  demonstrated  that:  (1)  folic
cid  prevents  congenital  heart  defects;  (2)  homocysteine
evels  have  a  strong  correlation  with  cardiovascular  dis-
ase  genesis,  and  (3)  female  sex  hormone  deﬁciency  is
n  important  factor  for  homocysteine  increase.30,43 How-
ver,  polymorphisms  C677T  and  A1298C  in  the  MTHFR
5,10-methylenetetrahydrofolate  reductase)  gene  were  not
ssociated  with  homocysteine  levels  in  Brazilian  patients
ith  TS,  and  these  were  not  higher  in  patients  with  the
isk  haplotype.30 Also  in  relation  to  the  risk  of  congenital
eart  defects,  disruption  of  the  folate  pathway  contributed
o  the  incidence  of  atrioventricular  septal  defect  in  individ-
als  with  Down  syndrome.44 It  would  be  interesting  to  carry
ut  a  study  focusing  on  TS,  due  of  the  high  incidence  of
ardiac  abnormalities  in  this  group  of  patients.
hromosomal  nondisjunctionS  is  an  aneuploidy  caused  by  chromosomal  nondisjunc-
ion,  which  occurs  when  homologous  chromosomes  or  sister
hromatids  fail  to  separate,  with  advanced  maternal  age
eing  a  risk  factor.  Genetic  polymorphisms  that  alter
u
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nzymes  involved  in  folate  metabolism,  such  as  the  enzyme
ethylenetetrahydrofolate  reductase  (MTHFR)  can  lead  to
NA  hypomethylation  and  increase  the  risk  of  chromoso-
al  nondisjunction  and  thus,  of  TS.  The  MTHFR  gene  is
ocated  on  1p36.3  and  includes  two  polymorphisms:  sub-
titution  of  cytosine  by  thymine  at  nucleotide  677  (C677T)
nd  adenine  by  cytosine  at  nucleotide  1298  (A1298C),  resul-
ing  in  decreased  MTHFR  activity,  interfering  with  the  folate
etabolism.
Three  studies  analyzed  polymorphisms  in  this  gene  in
razilian  patients  with  TS.28--30 The  results  regarding  the
ontribution  of  these  polymorphisms  to  the  etiology  of  TS
re  conﬂicting,  as  the  C677T  SNP  was  associated  with  TS  in
ne  study,28 whereas  in  the  others  it  was  A1298C.29,30 Three
ndependent  meta-analyses45--47 positively  associated  MTHFR
677T  and  Down’s  Syndrome:  one  of  them  included  28  case-
ontrol  studies,45 and  the  other,  22  studies  for  MTHFR  C677T
nd  15  for  MTHFR  A1298C.47
The  genetic  polymorphisms  analyzed  here  seem  to  inﬂu-
nce  the  severity  of  the  clinical  manifestations  of  TS,  as  well
s  response  to  treatment.  In  this  sense,  future  studies  could
ndicate  their  use  in  clinical  practice  as  molecular  markers
or  diagnosis  and  prognosis.  Another  interesting  ﬁnding  is
hat  a detailed  analysis  of  Table  1  shows  that  41%  (7/17)
f  the  studies  on  genetic  polymorphisms  in  TS  were  per-
ormed  by  Brazilian  researchers.  Brazil  has  a  high  degree
f  miscegenation  and  genetic  polymorphisms  are  related  to
thnic  origin.  However,  only  one  of  the  studies  brieﬂy  men-
ioned  that  the  country  is  a  heterogeneous  nation  consisting
f  populations  descended  from  different  ethnicities.30 There
s  a  consensus  in  the  literature  on  the  need  to  analyze  the
ame  polymorphism  in  different  populations,  as  a  genetic
ssociation,  although  valid  for  a  speciﬁc  population,  may
ot  be  relevant  to  individuals  from  a  different  ethnic  group.
tratiﬁcation  of  the  groups  regarding  ethnicity  is  not  so  sim-
le,  as  neither  skin  color  nor  region  of  origin  can  adequately
ifferentiate  a  mixed  population.48
Another  important  issue  addressed  in  only  a  few
tudies18,25 concerns  study  limitations  in  relation  to  sample
ize.  All  of  the  articles  included  in  this  review  reported  the
eed  for  further  studies  in  ‘‘Discussion’’  section,  but  did
ot  provide  a  description  of  possible  sources  of  error  and
heir  effect  on  data.  Regarding  the  study  sample,  research
n  genetic  polymorphisms  in  human  diseases  must  have  the
tatistical  power  deﬁned  as  the  probability  of  the  study  to
etect  an  effect  when  it  exists.  A  critique  of  the  17  scientiﬁc
rticles  analyzed  here  is  that  only  one  of  them  established
he  statistical  power.25
onclusions
enetic  polymorphisms  seem  to  be  associated  with  TS,
s  most  studies  showed  a  positive  association  (11/17).
owever,  considering  the  few  published  studies  and  contra-
ictory  ﬁndings,  probably  due  to  differences  in  ethnicity  of
he  analyzed  samples,  studies  carried  out  in  different  pop-
lations  are  desirable  in  order  to  clarify  the  role  of  these
NPs  for  the  clinical  signs  and  etiology  of  this  chromosomal
isorder.  Moreover,  multicenter  studies  with  a  large  num-
er  of  patients  with  TS  are  necessary  for  the  results  to  have
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statistical  power,  which  is  important  in  studies  with  genetic
polymorphisms  in  human  diseases.
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